Formulation
Lyophilization of pharmaceutical and biopharmacetical products
Article REF: PHA2026 V1
Formulation
Lyophilization of pharmaceutical and biopharmacetical products

Author : Alain HEDOUX

Publication date: September 10, 2013, Review date: February 12, 2021 | Lire en français

Logo Techniques de l'Ingenieur You do not have access to this resource.
Request your free trial access! Free trial

Already subscribed?

4. Formulation

The composition of the formulation will depend on whether the active ingredient to be lyophilized is a small molecule or a biomolecule. Biopharmaceutical products are often highly potent, needing to be administered in low doses, and require the addition of bulking agents to preserve the elegant appearance of the final product. Proteins or peptides are also distinguished from low-molecular-weight molecules by their marginal stability in solution, due to temperature effects (high and low), pH variations, the presence of ice crystals and significant dehydration. To avoid protein degradation during the freeze-drying cycle, and during storage in the dry state, numerous excipients are used, often in an empirical manner, transforming formulations into highly complex cooking recipes. The role of each type of excipient can be briefly described. The nature and concentration of these excipients have...

You do not have access to this resource.
Logo Techniques de l'Ingenieur

Exclusive to subscribers. 97% yet to be discovered!

You do not have access to this resource. Click here to request your free trial access!

Already subscribed?


Article included in this offer

"Drugs and pharmaceuticals"

( 125 articles )

Complete knowledge base

Updated and enriched with articles validated by our scientific committees

Services

A set of exclusive tools to complement the resources

View offer details
Contact us